非瓣膜病心房颤动病人华法林抗凝治疗安全性评价

目的:评价非瓣膜病心房颤动(房颤)用华法林抗凝治疗的安全性。方法:选择符合该研究抗凝标准的98例心房颤动病人随机分为两组,华法林治疗组(治疗组)46例,给予华法林3mg/d开始监测凝血酶原时间(PT)及国际标准化比值(INR),7～15天使INR达到2.0～3.0范围内,以后每月查1次INR。若病人增加或减少药物、有出血倾向时随时再测INR。阿司匹林对照组(对照组)52例,给予阿司匹林100mg/d口服2次,密切随访。结果:治疗组9～15d(平均10.1±2.2)INR达2.0～3.0(平均2.25±0.11),其中INR在1.8～2.5(平均1.92±0.23)之间者占90.7%,治疗组未出现脑梗死,而对照组有3例发生脑梗死,两组总不良反应率差异无显著性.。结论:非瓣膜病房颤病人选择华法林3mg/d加强服药后监测及各药物间的相互作用,使INR保持在2.0～3.0之间是有效、安全的。

Assessment of security of anticoagulation of warfarin in patients with atrial fibrillation not due to valvular disease

Objective To assess the security of anticoagulation of warfarin in patients with atrial fibrillation not due to valvular disease.Methods 98patients of atrial fibrillation not due to valvular disease were divided into two groups randomly Warfarin group(46subjects)started with dose of 3mg /d.PT and INR were detected.INR were controlled between2.0～3.0.After7～15days PT and INR were detected monthly.If the dose of warfarin were increased or decreased or the patients inclined to harmorrhage,INR was detected at any time.The control group were taken aspirin100mg /d twice a day.Results Warfarin group attained INR to2.0～3.0after9～15days.The patients whose INR in1.8～2.5were90.7%.No patient was found cerebral embolism in warfarin treatment group however3in the control group.There were no significant difference in adverse effect between two groups.Conclusion It is effective and safe to keep INR between2.0～3.0for the patients of atrial fibrillation not due to valvular disease with the dose of 3mg /d warfarin.